Parnassus Investments’s Insmed INSM Stock Holding History

Parnassus Investments’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-69,515	Closed	-$11.4M	–	142
2026 Q1	$11.4M	Buy	69,515 +17,872	+35%	+$2.75M	0.03%	117
2025 Q4	$8.99M	Buy	51,643 +42,916	+492%	+$7.83M	0.02%	124
2025 Q3	$1.26M	Buy	8,727 +797	+10%	+$97.6K	﹤0.01%	135
2025 Q2	$798K	Buy	+7,930	New	+$606K	﹤0.01%	136

Other funds holding INSM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Parnassus Investments's INSM Position: Q2 2026 in Review

Parnassus Investments sold out of Insmed (INSM) in Q2 2026, closing a stake of 69,515 shares — an estimated $11.4M sold.

Parnassus Investments first reported a position in INSM in Q2 2025 and held it in 4 quarters. The position peaked at $11.4M in Q1 2026. 663 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

Parnassus Investments reported no remaining Insmed position as of Q2 2026 after selling out during the quarter.
Parnassus Investments sold 69,515 Insmed shares in Q2 2026, an estimated $11.4M.
Parnassus Investments first reported a position in Insmed in Q2 2025 and held it in 4 quarters.
Parnassus Investments's Insmed position peaked at $11.4M in Q1 2026.
663 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on Parnassus Investments's 13F filing for Q2 2026, filed 29 Jul 2026.